Member Info for Titania

Looks very encouraging I agree but are we of limited availability?

"For promising agents with limited availability, a phase 3 evaluation may occur at a later time."

I note Janet Wood**** from the FDA is a non voting board member of the foundation below.

https://reaganudall.org/clinical-trial/activ-2-study-outpatients-covid-19

https://reaganudall.org/clinical-trial/activ-2-study-outpatients-covid-19

https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials

Looks like everything on Activ-2 is now on phase 2/3 whatever that means!

https://www.abcactionnews.com/news/region-hillsborough/temple-terrace-research-center-testing-4-new-covid-19-treatments

It made me feel a Wohl lot better too!

https://www.wbay.com/2021/06/30/combat-covid-initiative-looking-more-people-join-clinical-treatment-trials/

“The key thing we need is, and this is what the federal government is really investing in, is easy to take therapies, ideally pills … so something you can take, maybe take it for a few days and it knocks out the COVID or maybe an inhaler therapy,” said Dr. Wohl. “Even a shot. If you went to a clinic and you just got a one-time shot, that’s better than an infusion.”

https://www.newschannel5.com/news/local-covid-19-positive-participants-needed-for-treatment-study

Accepting vaccinated breakthrough cases as well.

Filed on 8th July at Companies House.

https://find-and-update.company-information.service.gov.uk/company/05233429

Apologies if this has already been posted and referenced.

https://www.mynews13.com/fl/orlando/news/2021/07/01/volunteers-needed-for-covid-19-treatment-clinical-trials

https://onlinelibrary.wiley.com/doi/10.1002/ccr3.3997

Looks like he is on side with the interferon approach!

UK infection numbers are grim. But recommendation 4 is good : we need to continue pushing on treatments. In April this year, we belatedly launched our antiviral taskforce. We need to build on the success of finding Dexamethasone, to develop and stockpile a basket of other treatments to further decouple catching Covid from death. In particular, we should focus on broad-spectrum antivirals as these are likely to work on future variants.

https://www.spectator.co.uk/article/the-covid-battle-sajid-javid-still-has-to-face

Analysis needs to be age adjusted. These are different populations. The vaccinated are older.

https://www.synairgen.com/contact-us/employment-opportunities/

Sorry in advance if this has already been posted.

https://www.news-medical.net/news/20210623/SARS-CoV-N-protein-elicits-production-of-IFN-ceb2-by-provoking-ubiquitination-of-RIG-I-finds-study.aspx

"This study observed that the SADS-CoV N protein targets RIG-I to inhibit IFN-ß promoter activity."

https://news.cision.com/astrazeneca/r/astrazeneca-prices-a--7bn-bond-offering,c3353678

Big money being raised by large pharmas recently! Maybe a few strategic positions could be built!

As before approx same size trade on AVCT at a similar time!

News could be soon but it will not be talked about in any strategic documents in advance.

That's my best shot at translating it. French isn't my strong point and the google translation is stilted.

Ça reviendra assez vite à dire tout le monde, mais sans le dire Smirking face.
J'aurais plus vu l'IFN inh ou les mab (pour les riches) dans une telle stratégie contact, avant reprise épidémique.

It will come back pretty quickly to tell everyone, but without saying it Smirking face.
I would no longer have seen IFN inh or mabs (for the rich) in such a contact strategy, before epidemic resumption.

https://www.allplacesmap.com/news/world/us-eager-to-involve-indian-investigators-in-covid-19-global-clinical-trials-dr-anthony-fauci.html

https://twitter.com/search?q=Delhi%20covid%20trial&src=typed_query&f=live